Albertsen to discuss “contemporary recommendations” on AS at AUA annual meeting

In one of the more important lectures at the upcoming annual meeting of the American Urological Association, starting in Orlando in a couple of weeks’ time, Dr. Peter Albertsen will be reviewing contemporary recommendations on the practice of active surveillance (AS) for men with low- and very low-risk prostate cancer. … READ MORE …

One man’s route to active surveillance as a first-line management strategy

When CT learned that he had low-grade, organ-confined prostate cancer, he did not decide to get surgical or other therapeutic interventions immediately, based on the guidance of the first doctors he saw. Instead, he decided to actively monitor his disease and adjust his lifestyle habits with guidance from a team of specialists. … READ MORE …

How active should “active surveillance” really be? Are we being overly cautious?

There are a couple of brief but interesting new articles about active surveillance by Dr. Oliver Sartor and Laurence Klotz on the CancerNetwork.com web site this week. They deal with differing perceptions about the application of active surveillance. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

What happened early this morning at the GU Cancers Symposium

So … as a couple of readers have already realized … the sheer quantity of new and interesting data at the meeting is enormous, and your reporter is going to have to select what he tries to covers with care, ‘cos there’s no way to cover it all! … READ MORE …

New point of care PSA test … coming soon to your doctor’s office?

According to a media release issued last week by a relatively new company called True Diagnostics, Inc., they hope shortly to be able to introduce a new, “point of care” technical system that can be used to assay PSA levels from a “finger-prick” quantity of blood, thus allowing almost instant assessment of PSA levels in the doctor’s office. … READ MORE …

30 years follow-up of men with initially untreated, localized prostate cancer

A new article in European Urology offers interesting data on the natural history of localized prostate cancer, based on a cohort of 200+ Swedish patients followed for > 30 years. It is important to note immediately that none of these men was originally diagnosed in the PSA era. They all had some form of symptomatic disease at diagnosis. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,156 other followers